A compendium of cytogenetic abnormalities in myelofibrosis: Molecular and phenotypic correlates in 826 patients

British Journal of Haematology

Volumn 169, Issue 1, 2015, Pages 71-76

  Wassie, Emnet ^a   Finke, Christy ^a   Gangat, Naseema ^a   Lasho, Terra L ^a   Pardanani, Animesh ^a   Hanson, Curtis A ^a   Ketterling, Rhett P ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

CALR; JAK2; Karyotype; Myelofibrosis; Myeloproliferative

Indexed keywords

AGED; ANEMIA; ARTICLE; ASXL1 GENE; CALR GENE; CHROMOSOME ABERRATION; CYTOGENETICS; CYTOPENIA; EZH2 GENE; FEMALE; GENE; GENE MUTATION; HUMAN; IDH1 GENE; IDH2 GENE; JAK2 GENE; KARYOTYPE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METAPHASE; MPL GENE; MYELOID METAPLASIA; PHENOTYPE; PRIORITY JOURNAL; SF3B1 GENE; SRSF2 GENE; THROMBOCYTOPENIA; U2AF1 GENE; CLINICAL TRIAL; COMPLICATION; GENETICS; HUMAN CHROMOSOME; MIDDLE AGED;

ABNORMAL KARYOTYPE; AGED; ANEMIA; CHROMOSOMES, HUMAN; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; THROMBOCYTOPENIA;

EID: 84925038218     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13260     Document Type: Article

References (17)

1. Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791-4797.
2. Caramazza, D., Lasho, T.L., Finke, C.M., Gangat, N., Dingli, D., Knudson, R.A., Siragusa, S., Hanson, C.A., Pardanani, A., Ketterling, R.P. & Tefferi, A. (2010) IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 24, 2120-2122.
3. Caramazza, D., Begna, K.H., Gangat, N., Vaidya, R., Siragusa, S., Van Dyke, D.L., Hanson, C., Pardanani, A. & Tefferi, A. (2011) Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia, 25, 82-88.
4. Dewald, G.W., Broderick, D.J., Tom, W.W., Hagstrom, J.E. & Pierre, R.V. (1985) The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genetics and Cytogenetics, 18, 1-10.
5. Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F. & Tefferi, A. (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29, 392-397.
6. Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D., Them, N.C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G.I., Bagienski, K., Milanesi, C., Casetti, I.C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schonegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M. & Kralovics, R. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. The New England Journal of Medicine, 369, 2379-2390.
7. Lasho, T.L., Jimma, T., Finke, C.M., Patnaik, M., Hanson, C.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2012) SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood, 120, 4168-4171.
8. Li, B., Xu, J., Li, C., Gale, R.P., Xu, Z., Qin, T., Zhang, Y., Huang, G., Fang, L., Zhang, H., Pan, L., Hu, N., Qu, S. & Xiao, Z. (2014) Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis. American Journal of Hematology, 89, 1043-1046.
9. Plo, I., Nakatake, M., Malivert, L., de Villartay, J.P., Giraudier, S., Villeval, J.L., Wiesmuller, L. & Vainchenker, W. (2008) JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood, 112, 1402-1412.
10. Rice, K.L., Lin, X., Wolniak, K., Ebert, B.L., Berkofsky-Fessler, W., Buzzai, M., Sun, Y., Xi, C., Elkin, P., Levine, R., Golub, T., Gilliland, D.G., Crispino, J.D., Licht, J.D. & Zhang, W. (2011) Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer Journal, 1, e40.
11. Schanz, J., Tuchler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M.L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstocker, M., Nosslinger, T., Valent, P., Giagounidis, A., Aul, C., Lubbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Faderl, S., Pierce, S., Le Beau, M.M., Bennett, J.M., Greenberg, P., Germing, U. & Haase, D. (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. Journal of Clinical Oncology, 30, 820-829.
12. Simons, A., Shaffer, L.G. & Hastings, R.J. (2013) Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition. Cytogenetic and Genome Research, 2013, 141, 1-6.
13. St Antoine, A., Ketterling, M.N., Sukov, W.R., Lowman, J., Knudson, R.A., Sinnwell, J.P., Wiktor, A.E. & Ketterling, R.P. (2011) Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses. Archives of Pathology & Laboratory Medicine, 135, 915-919.
14. Tefferi, A., Jimma, T., Gangat, N., Vaidya, R., Begna, K.H., Hanson, C.A., Van Dyke, D.L., Caramazza, D. & Pardanani, A. (2011) Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood, 118, 4595-4598.
15. Tefferi, A., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R., Hanson, C.H., Maffioli, M., Caramazza, D., Passamonti, F. & Pardanani, A. (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia, 28, 1472-1477.
16. Vannucchi, A.M., Lasho, T.L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., Ketterling, R.P., Rotunno, G., Knudson, R.A., Susini, M.C., Laborde, R.R., Spolverini, A., Pancrazzi, A., Pieri, L., Manfredini, R., Tagliafico, E., Zini, R., Jones, A., Zoi, K., Reiter, A., Duncombe, A., Pietra, D., Rumi, E., Cervantes, F., Barosi, G., Cazzola, M., Cross, N.C. & Tefferi, A. (2013) Mutations and prognosis in primary myelofibrosis. Leukemia, 27, 1861-1869.
17. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.